TrialBlood advances2021

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

Tara L Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.